The overactive bladder: Review of current pharmacotherapy in adults. Part 2: Treatment options in cases refractory to anticholinergics

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 5, 2006, Pages 529-538

  Sahai, Arun ^a   Khan, Mohammed Shamin ^a   Arya, Manit ^b   John, Jason ^a   Singh, Rajinder ^a   Patel, Hitendra R H ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Bladder; Botulinum toxin; Detrusor overactivity; Idiopathic detrusor overactivity; Neurogenic detrusor overactivity; Non neurogenic detrusor overactivity; Overactive bladder; Resiniferatoxin

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CAPSAICIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; GENTAMICIN; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; RESINIFERATOXIN; TACHYKININ RECEPTOR ANTAGONIST;

BLADDER CAPACITY; CLINICAL TRIAL; CONSTIPATION; CYSTALGIA; DETRUSOR DYSSYNERGIA; DRUG DOSE REGIMEN; DRUG POTENTIATION; FLU LIKE SYNDROME; HEMATURIA; HUMAN; INJECTION SITE PAIN; MALAISE; MICTURITION; MUSCLE WEAKNESS; NEUROGENIC BLADDER; NEUROMODULATION; NONHUMAN; OVERACTIVE BLADDER; QUALITY OF LIFE; REVIEW; TREATMENT FAILURE; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE VOLUME; URODYNAMICS; XEROSTOMIA;

ADMINISTRATION, INTRAVESICAL; BOTULINUM TOXINS; CHOLINERGIC ANTAGONISTS; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, INVESTIGATIONAL; HUMANS; NEUROTOXINS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT FAILURE; URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE;

EID: 33645813567     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.5.529     Document Type: Review

References (57)

1. SZALLASI A, BLUMBERG PM: Vanilloid receptors: new insights enhance potential as a therapeutic target. Pain (1996) 68(2-3):195-208.
2. CHANCELLOR MB, DE GROAT WC: Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J. Urol. (1999) 162(1):3-11.
3. FOWLER CJ, JEWKES D, MCDONALD WI, LYNN B, DE GROAT WD: Intravesical capsaicin for neurogenic bladder dysfunction. Lancet (1992) 339:1239.
4. CRUZ F, GUIMARAES M, SILVA C, REIS M: Suppression of bladder hyperreflexia by intravesical resiniferatoxin. Lancet (1997) 350(9078):640-641.
5. CRUZ F: Mechanisms involved in new therapies for overactive bladder. Urology (2004) 63(Suppl. 3A):65-73.
6. LAZZERI M, BENEFORTI P, SPINELLI M, ZANOLLO A, BARBAGLI G, TURINI D: Intravesical resiniferatoxin for the treatment of hypersensitive disorder: a randomized placebo controlled study. J. Urol. (2000) 164(3 Pt 1):676-679.
7. LAZZERI M, SPINELLI M, BENEFORTI P, ZANOLLO A, TURINI D: Intravesical resiniferatoxin for the treatment of detrusor hyperreflexia refractory to capsaicin in patients with chronic spinal cord diseases. Scand. J. Urol. Nephrol. (1998) 32(5):331-334.
8. GIANNANTONI A, DI STASI SM, STEPHEN RL et al.: Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomised study. J. Urol. (2002) 167(4):1710-1714.
9. KIM JH, RIVAS DA, SHENOT PJ et al.: Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomised, placebo-controlled trial. J. Spinal Cord Med. (2003) 26(4):358-363.
10. SILVA C, RIBEIRO MJ, CRUZ F: The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J. Urol. (2002) 168(2):575-579.
11. KUO HC: Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions. J. Urol. (2003) 170(3):835-839.
12. YOKOYAMA T, NOZAKI K, FUJITA O, NOSE H, INOUE M, KUMON H: Role of C afferent fibers and monitoring of intravesical resiniferatoxin therapy for patients with idiopathic detrusor overactivity. J. Urol. (2004) 172(2):596-600.
13. KUO HC: Multiple intravesical instillation of low-dose resiniferatoxin is effective in the treatment of detrusor overactivity refractory to anticholinergics. Brit. J. Urol. Int. (2005) 95(7):1023-1027.
14. SILVA C, SILVA J, RIBEIRO MJ, AVELINO A, CRUZ F: Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial. Eur. Urol. (2005) 48(4):650-655.
15. GILL DM: Bacterial toxins: a table of lethal amounts. Microbiol. Rev. (1982) 46(1):86-94.
16. SIMPSON LL: Molecular pharmacology of botulinum toxin and tetanus toxin. Ann. Rev. Pharmacol. Toxicol. (1996) 26:427-453.
17. SCHIAVO G, PAPINI E, GENNA G, MONTECUCCO C: An intact interchain disulphide bond is required for the neurotoxicity of tetanus toxin. Infect. Immun. (1990) 58:4136-4141.
18. DE PAIVA A, ASHTON AC, FORAN P, SCHIAVO G, MONTECUCCO C, DOLLY JO: Botulinum A like type B and tetanus toxins fulfill criteria for being a zinc dependent protease. J. Neurochem. (1993) 61(6):2338-2341.
19. SCHIAVO G, MATTEOLI M, MONTECUCCO C: Neurotoxins affecting neuroexocytosis. Physiol. Rev. (2000) 80:717-766.
20. ANGAUT-PETIT D, MOLGO J, COMELLA JX, FAILLE L, TABTI N: Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience (1990) 37:799-808.
21. SCHURCH B, STOHRER M, KRAMER G, SCHMID DM, GAUL G, HAURI D: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injury patients: a new alternative to anticholinergic drugs? Preliminary results. J. Urol. (2000) 164:692-697.
22. APOSTOLIDIS A, DASGUPTA P, FOWLER CJ: Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur. Urol. (in press).
23. APOSTOLIDIS A, POPAT R, YIANGOU Y et al.: Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibres following intra-detrusor injections of Botulinum toxin for human detrusor overactivity. J. Urol. (2005) 174:977-983.
24. AOKI KR: Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology (2005) 26(5):785-793.
25. LEIPPOLD T, REITZ A, SCHURCH B: Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur. Urol. (2003) 44(2):165-174.
26. SAHAI A, KHAN M, FOWLER CJ, DASGUPTA P: Botulinum toxin for the treatment of lower urinary tract symptoms: a review. Neurourol. Urodyn. (2005) 24(1):2-12.
27. HARPER M, FOWLER CJ, DASGUPTA P: Botulinum toxin and its applications in the lower urinary tract. Brit. J Urol. Int. (2004) 93(6):702-706.
28. KESSLER TM, DANUSER H, SCHUMACHER M, STUDER UE, BURKHARD FC: Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol. Urodyn. (2005) 24(3):231-236.
29. BAGI P, BIERING-SORENSEN F: Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J. Urol. Nephrol. (2004) 38(6):495-498.
30. HAJEBRAHIMI S, ALTAWEEL W, CADORET J, COHEN E, CORCOS J: Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. Can. J. Urol. (2005) 12(1):2543-2546.
31. KLAPHAJONE J, KITISOMPRAYOONKUL W, SRIPLAKIT S: Botulinum toxin type A injections for treating neurogenic detrusor overactivity combined with low-compliance bladder in patients with spinal cord lesions. Arch. Phys. Med. Rehabil. (2005) 86(11):2114-2118.
32. REITZ A, STOHRER M, KRAMER G et al.: European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur. Urol. (2004) 45(4):510-515.
33. KUO H-C: Therapeutic effects of suburothelial injection of borulinum A toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology (in press).
34. SCHURCH B, DE SEZE M, DENYS P et al.: Botox Detrusor Hyperreflexia Study Team: Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J. Urol. (2005) 174(1):196-200.
35. HARPER M, POPAT RB, DASGUPTA A, APOSTOLIDIS A, FOWLER CJ, DASGUPTA P: A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int. (2003) 92(3):325-326.
36. POPAT R, APOSTOLIDIS A, KALSI V, GONZALES G, FOWLER CJ, DSGUPTA P: A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. (2005) J. Urol. 174:984-989.
37. SAHAI A, KALSI V, KHAN MS, FOWLER CJ: Techniques of intradetrusor administration of botulinum toxin. Brit. J. Urol. Int. (in press).
38. RAPP DE, LUCIONI A, KATZ EE, O'CONNOR RC, GERBER GS, BALES GT: Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology (2004) 63(6):1071-1075.
39. SMITH CP, NISHIGUCHI J, O'LEARY M, YOSHIMURA N, CHANCELLOR MB: Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology (2005) 65(1):37-41.
40. KUO HC: Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology (2005) 66(1):94-98.
41. WERNER M, SCHMID DM, SCHUSSLER B: Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am. J. Obstet. Gynecol. (2005) 192(5):1735-1740.
42. SCHULTE-BAUKLOH H, WEISS C, STOLZE T et al.: Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur. Urol. (2005) 48(6):984-990.
43. DYKSTRA DD, PRYOR J, GOLDISH G: Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: a case report. Arch. Phys. Med. Rehabil. (2003) 84:1399-1400.
44. REITZ A, SCHURCH B: Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J. Urol. (2004) 171(2 Pt 1):804.
45. PISTOLESI D, SELLI C, ROSSI B, STAMPACCHIA G: Botulinum toxin type B for type A resistant bladder spasticity. J. Urol. (2004) 171(2 Pt 1):802-803.
46. DYKSTRA D, ENRIQUEZ A, VALLEY M: Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int. Urogynecol. J. Pelvic Floor Dysfunct. (2003) 14(6):424-426.
47. GHEI M, MARAJ BH, MILLER R et al.: Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J. Urol. (2005) 174(5):1873-1877.
48. GIANNANTONI A, DI STASI SM, STEPHEN RL, BINI V, COSTANTINI E, PORENA M: Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomised study. J. Urol. (2004) 172(1):240-243.
49. SCHULTE-BAUKLOH H, WEISS C, STOLZE T, STURZEBECHER B, KNISPEL HH: Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology (2005) 66(1):82-87.
50. GROSSE J, KRAMER G, STOHRER M: Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur. Urol. (2005) 47(5):653-659.
51. WYNDAELE JJ, VAN DROMME SA: Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord (2002) 40(11):599-600.
52. SANTOS JI, SWENSEN P, GLASGOW LA: Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics (1981) 68(1):50-54.
53. ANDERSSON KE, PEHRSON R: CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention. Drugs (2003) 63(23):2595-2611.
54. YOSHIMURA N, CHANCELLOR MB: Current and future pharmacological treatment for overactive bladder. J. Urol. (2002) 168(5):1897-1913.
55. OUSLANDER JG: Management of overactive bladder. N. Engl. J. Med. (2004) 350(8):786-799.
56. KUMAR V, TEMPLEMAN L, CHAPPLE CR, CHESS-WILLIAMS R: Recent developments in the management of detrusor overactivity. Curr. Opin. Urol. (2003) 13(4):285-291.
57. ABRAMS P, BLAIVAS JG, FOWLER CJ et al.: The role of neuromodulation in the management of urinary urge incontinence. Brit. J. Urol. Int. (2003) 91(4):355-359.